We profile Queensland veterinary biotech Plasvacc, which develops plasma products as an alternative to antibiotics.

With AusBiotech 2007 being held in Brisbane next week, ALS takes its bi-annual survey of the state of the industry.

Two new vaccines against rotavirus infection have been added to the PBS.

Last year wasn't the best on record for the Australian biotechnology industry but this year and the next look much more promising. Share prices are up, investors are showing more interest and there are a lot of good stories to tell and sell.

The cervical cancer vaccine Gardasil will be available to 12 to 13-year-old girls next year after manufacturer CSL and the federal government agreed on price.

It hasn't been the best year on record for the Australian biotechnology industry but things should improve somewhat next year. Kate McDonald reports that the fragility of the sector is sure to be a topic of discussion at this year's AusBiotech conference.

The value of the Australian life science sector declined 3.5 per cent during the fourth quarter, ending 30 June 2006, according to the latest BioForum report from PricewaterhouseCoopers (PwC).

Just as the HPV vaccine Gardasil receives FDA approval, an argument has broken out between the researchers involved in the vaccine's development. So who patented what?

A leading researcher has raised the ire of CSL (ASX:CSL), saying the Melbourne company is "making the wrong vaccine for bird flu."

The Australian life sciences industry has grown significantly in the past five years and shows signs of a positive future, according to the 15th edition of PricewaterhouseCoopers' quarterly BioForum report.

Melbourne's CSL (ASX:CSL) today reported a net profit after tax of AUD$176.4 million for the first half of the financial year, up 34 per cent from the previous first half, and has upgraded its full year profit forecast by about 15 per cent to $335 to $350 million.